{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:50:19Z","timestamp":1760147419115,"version":"3.37.3"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"6","funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research National Institute for Health Research (NIHR)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research National Institute for Health Research (NIHR)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1093\/omcr\/omx025","type":"journal-article","created":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T00:29:41Z","timestamp":1497486581000},"source":"Crossref","is-referenced-by-count":1,"title":["Early eculizumab use in atypical haemolytic uraemic syndrome in a Jehovah\u2019s Witness refusing blood products"],"prefix":"10.1093","volume":"2017","author":[{"given":"May","family":"Al-Shaghana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Bentall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Jesky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Lester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Lipkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,6,15]]},"reference":[{"key":"key\n\t\t\t\t20170615002932_omx025C1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1525-139X.2011.01035.x","article-title":"Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange","volume":"25","year":"2012","journal-title":"Semin Dial"},{"key":"key\n\t\t\t\t20170615002932_omx025C2","first-page":"27","article-title":"An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document","volume":"33","year":"2013","journal-title":"Nefrologia"},{"key":"key\n\t\t\t\t20170615002932_omx025C3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/j.ajkd.2012.07.028","article-title":"Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab","volume":"61","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20170615002932_omx025C4","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170615002932_omx025C5","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","year":"2013","journal-title":"N Eng J Med"},{"key":"key\n\t\t\t\t20170615002932_omx025C6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialized service in England for atypical haemolytic uraemic syndrome-the first year\u2019s experience","volume":"109","year":"2016","journal-title":"QJM"},{"key":"key\n\t\t\t\t20170615002932_omx025C7","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"year":"2015","author":"NICE","key":"key\n\t\t\t\t20170615002932_omx025C8"},{"key":"key\n\t\t\t\t20170615002932_omx025C9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/AOG.0b013e31828e2612","article-title":"Eculizumab for atypical hemolytic uremic syndrome in pregnancy","volume":"122","year":"2013","journal-title":"Obstet Gynecol"},{"key":"key\n\t\t\t\t20170615002932_omx025C10","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01090209","article-title":"Complement inhibitor eculizumab in atypical hemolytic uremic syndrome","volume":"4","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170615002932_omx025C11","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood-2013-11-516237","article-title":"How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome","volume":"123","year":"2014","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170615002932_omx025C12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/1098-1101(2000)15:4<266::AID-JCA9>3.0.CO;2-9","article-title":"Management of a Jehovah\u2019s witness with thrombotic thrombocytopaenic purpura\/haemolytic uraemic syndrome","volume":"15","year":"2000","journal-title":"J Clin Apher"},{"key":"key\n\t\t\t\t20170615002932_omx025C13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jca.21325","article-title":"Successful management of thrombotic thrombocytopenic purpura in a Jehovah\u2019s Witness without plasma exchange","volume":"30","year":"2015","journal-title":"J Clin Apher"},{"key":"key\n\t\t\t\t20170615002932_omx025C14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/jca.20150","article-title":"Successful management of a Jehovah\u2019s Witness with thrombotic thrombocytopenic purpura unwilling to be treated with therapeutic plasma exchange","volume":"22","year":"2007","journal-title":"J Clin Apher"},{"author":"Joint Formulary Committee","key":"key\n\t\t\t\t20170615002932_omx025C15"},{"key":"key\n\t\t\t\t20170615002932_omx025C16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/jme.29.5.275","article-title":"Applying the four principles","volume":"29","year":"2003","journal-title":"J Med Ethics"},{"key":"key\n\t\t\t\t20170615002932_omx025C17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20170615002932_omx025C18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/ki.2009.472","article-title":"Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome","volume":"77","year":"2010","journal-title":"Kidney Int"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2017\/6\/omx025\/17715607\/omx025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T11:29:23Z","timestamp":1526642963000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article-lookup\/doi\/10.1093\/omcr\/omx025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6,15]]},"published-print":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omx025","relation":{},"ISSN":["2053-8855"],"issn-type":[{"type":"electronic","value":"2053-8855"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}